Mitotane liposomes for potential treatment of adrenal cortical carcinoma : ex vivo intestinal permeation and in vivo bioavailability

Mitotane liposomes for potential treatment of adrenal cortical carcinoma : ex vivo intestinal permeation and in vivo bioavailability

Patricia Zancanella, Daniele M. L. Oliveira, Bonald H. de Oliveira, Thiago D. Woiski, Cesar C. Pinto, Maria H. A. Santana, Eliana B. Souto

ARTIGO

Inglês

The adrenal cortical carcinoma (ACC) treatment, for which mitotane (o,p′-DDD) is the drug of choice, still remains a challenge both because of the well-known solubility problems of the drug, and its serious side effects. Mitotane is currently administered as oral tablets. The loading of mitotane...

FUNDAÇÃO DE APOIO À PESQUISA E À INOVAÇÃO TECNOLÓGICA DO ESTADO DE SERGIPE - FAPITEC

FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP

CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQ

Fechado

Mitotane liposomes for potential treatment of adrenal cortical carcinoma : ex vivo intestinal permeation and in vivo bioavailability

Patricia Zancanella, Daniele M. L. Oliveira, Bonald H. de Oliveira, Thiago D. Woiski, Cesar C. Pinto, Maria H. A. Santana, Eliana B. Souto


										

Mitotane liposomes for potential treatment of adrenal cortical carcinoma : ex vivo intestinal permeation and in vivo bioavailability

Patricia Zancanella, Daniele M. L. Oliveira, Bonald H. de Oliveira, Thiago D. Woiski, Cesar C. Pinto, Maria H. A. Santana, Eliana B. Souto

    Fontes

    Pharmaceutical development and technology

    (2020)